Free Trial

Cooper Companies Q2 2024 Earnings Report

Cooper Companies logo
$95.30 -0.04 (-0.04%)
As of 02/4/2025 04:00 PM Eastern

Cooper Companies EPS Results

Actual EPS
$0.85
Consensus EPS
$0.83
Beat/Miss
Beat by +$0.02
One Year Ago EPS
$0.77

Cooper Companies Revenue Results

Actual Revenue
$942.60 million
Expected Revenue
$948.07 million
Beat/Miss
Missed by -$5.47 million
YoY Revenue Growth
+7.40%

Cooper Companies Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Cooper Companies Earnings Headlines

Brunswick Corp (BC) Director Nancy Cooper Sells 433 Shares
Evolent Health Strengthens Board with Strategic Changes
Starting 2025 Strong: 2 AI Stocks Under $10 You Can’t Miss
As we step into 2025, artificial intelligence (AI) continues to revolutionize industries with groundbreaking advancements. From the surge in generative AI technologies transforming creative processes to AI-driven automation enhancing operational efficiencies, the landscape is brimming with innovation. These rapid developments are creating lucrative opportunities for investors who recognize the potential of emerging AI companies.
CooperCompanies Announces Release Date for First Quarter 2025
Baxter Announces CEO Retirement and Appointment of COO
See More Cooper Companies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cooper Companies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cooper Companies and other key companies, straight to your email.

About Cooper Companies

Cooper Companies (NASDAQ:COO), together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including endosee endometrial imaging products, fetal pillow cephalic elevation devices for use in cesarean sections, illuminated speculum products, lone star retractor systems, loop electrosurgical excision procedure products, mara water ablation systems, paragard contraceptive IUDs, point-of-care, and uterine positioning products, as well as cryostorage, such as cord blood and cord tissue storage; fertility products and services, such as fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

View Cooper Companies Profile

More Earnings Resources from MarketBeat